Industry Briefs: November 26, 2012

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Nov 29, 2012
By PharmTech Editors

Company News

Algeta and Ablynx have formed a research collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies, a proprietary group of antibody-derived proteins. Read More

Cleveland BioLabs and Panacela Labs have announced an award of a contract valued at 146 million rubles ($4.6 million), with the Ministry of Industry and Trade of the Russian Federation for the development of Xenomycins, a family of compounds in development as anti-infective agents. Read More

Impax Laboratories will collaborate with Perrigo Company on the development, manufacturing, and commercialization of an extended topical generic-drug product. Read More

Unigene Laboratories and Tarix Pharmaceuticals have entered into a definitive licensing agreement to develop an oral formulation of TXA127, Tarix’s lead peptide drug candidate Read More

People News

Cambridge Major Laboratories has appointed Prasad Raje as vice-president of science and technology. Read More

Dr. Reddy’s Laboratories has appointed Umang Vohra as executive vice-president and head of the company’s North America generic-drug business, effective January 2013, and Saumen Chakraborty as chief financial officer, effective Jan. 2, 2013. Read More